BRIEF-Harbour Biomed Signs License Agreement With Windward Bio For HBM9378

Reuters
10 Jan

Jan 10 (Reuters) - Hbm Holdings Ltd :

* HARBOUR BIOMED ANNOUNCES LICENSE AGREEMENT WITH WINDWARD BIO FOR HBM9378/SKB378, AN ANTI-TSLP FULLY HUMAN ANTIBODY FOR IMMUNOLOGICAL DISEASES

* HBM HOLDINGS LTD - HARBOUR BIOMED AND KELUN-BIOTECH ELIGIBLE FOR UP TO $970 MILLION UPFRONT AND MILESTONE PAYMENTS

* HBM HOLDINGS: $45 MILLION UPFRONT & NEAR-TERM MILESTONE PAYMENTS INCLUDE BOTH CASH PAYMENT & EQUITY INTEREST IN WINDWARD BIO'S PARENT COMPANY

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10